XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES
12 Months Ended
Sep. 30, 2023
INCOME TAXES  
INCOME TAXES

NOTE I – INCOME TAXES

The income tax provision (benefit) for the fiscal years ended September 30, 2023 and 2022 consists of the following:

    

2023

    

2022

Federal:

Current

$

 

$

Deferred

 

(3,249,000)

 

(2,781,000)

 

(3,249,000)

 

(2,781,000)

State and local:

 

 

Current

 

 

Deferred

 

(1,161,000)

 

(852,000)

 

(1,161,000)

 

(852,000)

Foreign:

Current

Deferred

(121,000)

11,000

 

 

Change in valuation allowance

 

4,531,000

 

3,622,000

 

 

Income tax provision (benefit)

$

 

$

NOTE I – INCOME TAXES, continued

The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory rate to losses before income tax expense for the years ended September 30, 2023 and 2022 as follows:

    

2022

    

2022

 

Statutory federal income tax rate

 

21.00

%  

21.00

%

Statutory state and local income tax rate (1%, as of September 30, 2022 and 2021), net of federal benefit

 

9.56

%  

6.20

%

Stock based compensation

 

(1.76)

%

(5.01)

%

Permanent differences related to warrants

1.80

%

14.60

%

Other permanent differences

 

1.97

%  

1.70

%

Canada NOL

1.28

%  

0.00

%  

Federal R&D Credit

9.93

%  

3.83

%  

Change in deferred tax rate

1.67

%

1.56

%

Change in valuation allowance

 

(45.45)

%  

(43.88)

%

Effective tax rate

 

0.00

%  

0.00

%

Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:

September 30, 

    

2023

    

2022

Deferred tax assets (liabilities):

 

  

 

  

Stock based compensation

$

993,000

$

847,000

Depreciation and amortization

 

440,000

 

113,000

Net operating loss carry forward

 

25,250,000

 

22,872,000

Impairment of intangibles

227,000

205,000

Capitalized research and development

726,000

Lease liability

342,000

Tax credits

 

3,060,000

 

2,055,000

Other

 

324,000

 

397,000

Deferred tax assets

31,362,000

26,489,000

Intellectual property

(684,000)

ROU asset

(342,000)

(1,026,000)

Less: valuation allowance

 

(31,020,000)

 

(26,489,000)

Net deferred tax liability

$

(684,000)

$

As of September 30, 2023, the Company has approximately $101,526,000 of Federal and $56,892,000 of State net operating loss “NOL” carryforwards available. The Federal NOL of $60,374,000 begins to expire after 2022. The Federal NOLs generated in tax years beginning after December 31, 2017 have no expiration period due to the Tax Cuts and Jobs Act that was enacted in 2017. Pursuant to Internal Revenue Code Section 382, the Company’s ability to utilize the NOLs is subject to certain limitations due to changes in stock ownership in prior years, and as a result of the August 2022 public offering. The annual limitation ranges between $94,000 and $1,528,742 and any unused amounts can be carried forward to subsequent years.

The Company has provided a full valuation allowance against all of the net deferred tax assets based on management’s determination that it is more likely than not that the net deferred tax assets will not be realized in the future. The valuation allowance increased by $4,531,000.

The Company has Federal research and development credits of approximately $2,539,000 that will begin to expire after 2034. The Company also has state investment tax credits of $475,000 that will begin to expire after 2029.

NOTE I – INCOME TAXES, continued

On August 16, 2022, President Biden signed the Inflation Reduction Act,, which is effective for tax years beginning on or after January 1, 2023 For tax years beginning after December 31, 2021 the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or fifteen years beginning in 2022.  The Company included the impact of the research and development expenditures in its tax expense for the fiscal year ended September 30, 2023.  The Company will continue to monitor the possible future impact of changes in tax legislation.